Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
At a glance
- Drugs LY 3303560 (Primary) ; LY 3303560 (Primary) ; Florbetapir F 18; Flortaucipir-F-18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eli Lilly
- 19 Feb 2018 Planned End Date changed from 1 May 2019 to 1 Jun 2019.
- 19 Feb 2018 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019.
- 14 Feb 2018 Planned End Date changed from 1 Feb 2020 to 1 May 2019.